vs

Side-by-side financial comparison of ACRES Commercial Realty Corp. (ACR) and Apyx Medical Corp (APYX). Click either name above to swap in a different company.

ACRES Commercial Realty Corp. is the larger business by last-quarter revenue ($20.0M vs $19.2M, roughly 1.0× Apyx Medical Corp). ACRES Commercial Realty Corp. runs the higher net margin — 31.6% vs -6.8%, a 38.4% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs -6.5%). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 3.3%).

Piramal Realty is an Indian real estate company, founded in 2012 and headquartered in Mumbai, India. It is a part of the Piramal Group. The company focuses on the development of residential and commercial properties, with projects under development covering an estimated 15 million square feet. Among its notable projects include Piramal Aranya, Piramal Mahalaxmi, Piramal Revanta, Piramal Vaikunth and Piramal Agastya.

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

ACR vs APYX — Head-to-Head

Bigger by revenue
ACR
ACR
1.0× larger
ACR
$20.0M
$19.2M
APYX
Growing faster (revenue YoY)
APYX
APYX
+41.3% gap
APYX
34.7%
-6.5%
ACR
Higher net margin
ACR
ACR
38.4% more per $
ACR
31.6%
-6.8%
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
3.3%
ACR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACR
ACR
APYX
APYX
Revenue
$20.0M
$19.2M
Net Profit
$6.3M
$-1.3M
Gross Margin
62.6%
Operating Margin
30.8%
0.1%
Net Margin
31.6%
-6.8%
Revenue YoY
-6.5%
34.7%
Net Profit YoY
-32.0%
71.9%
EPS (diluted)
$-0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACR
ACR
APYX
APYX
Q4 25
$20.0M
$19.2M
Q3 25
$21.0M
$12.9M
Q2 25
$21.9M
$11.4M
Q1 25
$17.0M
$9.4M
Q4 24
$21.4M
$14.2M
Q3 24
$22.4M
$11.5M
Q2 24
$20.9M
$12.1M
Q1 24
$18.8M
$10.2M
Net Profit
ACR
ACR
APYX
APYX
Q4 25
$6.3M
$-1.3M
Q3 25
$18.0M
$-2.0M
Q2 25
$4.3M
$-3.8M
Q1 25
$-730.0K
$-4.2M
Q4 24
$9.3M
$-4.6M
Q3 24
$8.1M
$-4.7M
Q2 24
$6.4M
$-6.6M
Q1 24
$4.9M
$-7.6M
Gross Margin
ACR
ACR
APYX
APYX
Q4 25
62.6%
Q3 25
64.4%
Q2 25
62.3%
Q1 25
60.1%
Q4 24
63.0%
Q3 24
60.5%
Q2 24
61.7%
Q1 24
58.1%
Operating Margin
ACR
ACR
APYX
APYX
Q4 25
30.8%
0.1%
Q3 25
85.8%
-6.5%
Q2 25
19.8%
-22.6%
Q1 25
-3.8%
-32.4%
Q4 24
43.4%
-21.4%
Q3 24
36.4%
-31.6%
Q2 24
30.8%
-45.7%
Q1 24
26.2%
-64.6%
Net Margin
ACR
ACR
APYX
APYX
Q4 25
31.6%
-6.8%
Q3 25
85.8%
-15.4%
Q2 25
19.8%
-33.2%
Q1 25
-4.3%
-44.0%
Q4 24
43.5%
-32.5%
Q3 24
36.0%
-40.9%
Q2 24
30.6%
-54.0%
Q1 24
26.2%
-74.0%
EPS (diluted)
ACR
ACR
APYX
APYX
Q4 25
$-0.41
Q3 25
$1.34
Q2 25
$-0.10
Q1 25
$-0.80
Q4 24
$0.51
Q3 24
$0.36
Q2 24
$0.21
$-0.19
Q1 24
$0.07
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACR
ACR
APYX
APYX
Cash + ST InvestmentsLiquidity on hand
$83.8M
$31.7M
Total DebtLower is stronger
$1.6B
$37.5M
Stockholders' EquityBook value
$420.8M
$14.5M
Total Assets
$2.2B
$66.8M
Debt / EquityLower = less leverage
3.68×
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACR
ACR
APYX
APYX
Q4 25
$83.8M
$31.7M
Q3 25
$40.9M
$25.1M
Q2 25
$42.7M
$29.3M
Q1 25
$66.0M
$31.0M
Q4 24
$56.7M
$31.7M
Q3 24
$70.1M
$28.0M
Q2 24
$89.6M
$32.7M
Q1 24
$84.6M
$37.3M
Total Debt
ACR
ACR
APYX
APYX
Q4 25
$1.6B
$37.5M
Q3 25
$1.2B
$37.5M
Q2 25
$1.3B
$37.5M
Q1 25
$1.3B
$37.5M
Q4 24
$1.4B
$37.5M
Q3 24
$1.5B
$37.5M
Q2 24
$1.6B
Q1 24
$1.6B
Stockholders' Equity
ACR
ACR
APYX
APYX
Q4 25
$420.8M
$14.5M
Q3 25
$432.9M
$5.8M
Q2 25
$425.3M
$7.3M
Q1 25
$430.1M
$10.5M
Q4 24
$439.1M
$14.2M
Q3 24
$436.3M
$11.0M
Q2 24
$434.0M
$14.7M
Q1 24
$432.8M
$20.3M
Total Assets
ACR
ACR
APYX
APYX
Q4 25
$2.2B
$66.8M
Q3 25
$1.7B
$57.4M
Q2 25
$1.8B
$58.2M
Q1 25
$1.8B
$60.2M
Q4 24
$1.9B
$64.8M
Q3 24
$2.0B
$60.7M
Q2 24
$2.1B
$65.4M
Q1 24
$2.1B
$70.7M
Debt / Equity
ACR
ACR
APYX
APYX
Q4 25
3.68×
2.58×
Q3 25
2.76×
6.41×
Q2 25
3.10×
5.17×
Q1 25
2.97×
3.57×
Q4 24
3.12×
2.64×
Q3 24
3.43×
3.40×
Q2 24
3.67×
Q1 24
3.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACR
ACR
APYX
APYX
Operating Cash FlowLast quarter
$4.1M
$-2.5M
Free Cash FlowOCF − Capex
$-2.8M
FCF MarginFCF / Revenue
-14.6%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.65×
TTM Free Cash FlowTrailing 4 quarters
$-9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACR
ACR
APYX
APYX
Q4 25
$4.1M
$-2.5M
Q3 25
$-9.4M
$-3.5M
Q2 25
$11.8M
$-1.2M
Q1 25
$-4.6M
$-702.0K
Q4 24
$19.4M
$-2.9M
Q3 24
$8.4M
$-4.4M
Q2 24
$6.9M
$-4.3M
Q1 24
$3.3M
$-6.3M
Free Cash Flow
ACR
ACR
APYX
APYX
Q4 25
$-2.8M
Q3 25
$-4.1M
Q2 25
$-1.5M
Q1 25
$-757.0K
Q4 24
$-3.2M
Q3 24
$-4.6M
Q2 24
$-4.6M
Q1 24
$-6.4M
FCF Margin
ACR
ACR
APYX
APYX
Q4 25
-14.6%
Q3 25
-31.5%
Q2 25
-13.2%
Q1 25
-8.0%
Q4 24
-22.4%
Q3 24
-40.0%
Q2 24
-38.0%
Q1 24
-62.2%
Capex Intensity
ACR
ACR
APYX
APYX
Q4 25
1.4%
Q3 25
4.0%
Q2 25
2.3%
Q1 25
0.6%
Q4 24
1.7%
Q3 24
1.3%
Q2 24
2.4%
Q1 24
0.3%
Cash Conversion
ACR
ACR
APYX
APYX
Q4 25
0.65×
Q3 25
-0.52×
Q2 25
2.72×
Q1 25
Q4 24
2.08×
Q3 24
1.05×
Q2 24
1.07×
Q1 24
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACR
ACR

Other$10.8M54%
Pacmulti JVLLC$5.2M26%
Mccallum Jv Llc$2.5M12%
Office Complex$1.5M7%

APYX
APYX

Segment breakdown not available.

Related Comparisons